Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript

January 15, 2026 02:16:03 pm

Source: SeekingAlpha

2026-01-15 14:16:03 ET

Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy January 15, 2026 8:30 AM EST...

For further details see:

Ocugen, Inc.

-1.15% G/L:

$2.14 Last:

4,029,645 Volume:

$2.23 Open:

March 11, 2026 07:15:03 pm

March 04, 2026 09:55:52 am

March 04, 2026 08:15:00 am

March 04, 2026 06:00:52 am

Market Cap $478,717,026

Float 313,395,708

Insiders Ownership 0.26%

Institutions 38

Short Percent N/A

Industry Biotechnology & Life Sciences

Sector Healthcare

Country US

City Malvern